Amendments to the Claims

- 1. (Currently Amended) A pharmaceutical composition comprising an acidic aqueous solution comprising the The insulin analog A0^{Arg}A21^{Gly}B31^{Arg}B32^{Arg}-human insulin, wherein the insulin analog is not covalently bound to a fatty acid.
 - 2. (Canceled)
 - 3. (Canceled)
- 4. (Currently Amended) The <u>pharmaceutical</u> composition of claim <u>1</u> 3, further comprising one or more pharmaceutically acceptable excipients.
- 5. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claims 2-4</u>, further comprising a divalent metal cation.
- 6. (Currently Amended) The <u>pharmaceutical</u> composition of claim 5, wherein the divalent metal cation is zinc.
- 7. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claims 2-6</u>, further comprising a phenolic preservative.
- 8. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claims 2-6</u>, further comprising an isotonicity agent.
- 9. (Currently Amended) A method of treating hyperglycemia, the method comprising administering the <u>pharmaceutical composition</u> insulin analog of claim 1 to a subject in an amount sufficient to regulate blood glucose concentration in the subject.

- 10. (Currently Amended) A method of treating hyperglycemia, the method comprising administering the <u>pharmaceutical</u> composition of any one of claims 4, 5, 6, 7, 8 or 9 2-8 to a subject in an amount sufficient to regulate blood glucose concentration in the subject.
- 11. (Currently Amended) The method of claim 9 or 10, wherein the subject is treated for diabetes mellitus.
 - 12. (Canceled)

 13. (Canceled)

 14. (Canceled)

 15. (Canceled)

 16. (Canceled)

 17. (Canceled)

 18. (Canceled)

 19. (Canceled)

 20. (Canceled)

21. (Canceled)

22. (New) The method of claim 10, wherein the subject is treated for diabetes mellitus.